Trials / Completed
CompletedNCT00092768
A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)
A 26-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind, 2-Part Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Patients With Osteoarthritis (Study 1)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 500 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the safety and effectiveness of an investigational drug and an approved drug in the treatment of osteoarthritis of the knee and hip.
Detailed description
The duration of treatment is 26 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0663, etoricoxib | |
| DRUG | Comparator: celecoxib |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2005-02-01
- Completion
- 2005-02-01
- First posted
- 2004-09-28
- Last updated
- 2024-08-15
Source: ClinicalTrials.gov record NCT00092768. Inclusion in this directory is not an endorsement.